Your browser doesn't support javascript.
Molecular mechanisms underlying regulatory T cell deficiency and potential drugs in COVID-19
International Journal of Rheumatic Diseases ; 26(Supplement 1):384-385, 2023.
Article in English | EMBASE | ID: covidwho-2230772
ABSTRACT
Background/

Purpose:

The 2019 outbreak of coronavirus disease COVID-19 causes immune system disruption. Recent studies reported that the decrease or depletion of regulatory T cell (Treg) may be responsible for overstimulation of the immune system and lung damage in patients with severe COVID-19. This study aims to find the molecular mechanisms and genetic biomarkers associated with Tregs in COVID-19, providing new ideas for the treatment of COVID-19. Method(s) RNA sequencing data of peripheral blood mononuclear cells (PBMC) from 252 COVID-19 infected patients and 69 healthy controls (HC) were obtained from the GEO database. The Tregs composition of COVID-19 samples was quantified using the CIBERSORT deconvolution method. The differential genes (DEGs) were identified by the limma R package. Gene co-expression network analysis (WGCNA) was used to identify the gene. Differentially expressed Tregs-related genes (DETregRGs) were obtained by intersecting DEGs with the highly related modular genes obtained in the previous step. The potential biological functions and pathways of DETregRGs were then explored. Protein-protein interaction (PPI) networks were subsequently constructed to identify hub genes. In addition, the prediction of small molecule drugs for the potential treatment of COVID-19 was made using the CMap database. Result(s) After the weighted gene co-expression network analysis (WGCNA), the turquoise module was highly correlated with Treg expression and a total of 134 DEGs was identified as DETregRGs. These genes were mainly involved in GO biological processes, such as the inflammatory response, and T cell differentiation of thymus. Then, 11 hub genes (including RPS12, RPL21, RPS3A, CD8B, CD3D, TRAT1, RPS6, CD3E, CD28, RPL3, and CD4) were ranked based on Molecular Complex Detection (MCODE) analysis. The TregRG score of COVID-19 patients showed significantly lower than HC, calculated by the 'singscore' algorithms. After the signature query of the CMap database, the KU-0063794, an mTOR inhibitor ranked second in the negative enrichment score, may restore immune system dysregulation caused by increased Th17 differentiation and decreased Treg differentiation during SARS-CoV- 2 infection. Conclusion(s) Our study examined in detail the molecular mechanisms underlying the inadequacy of Tregs in patients with COVID-19 infection. mTOR inhibitors may improve COVID-19 symptoms by expanding Tregs which may be one of the potential therapeutic methods that need further investigation. (Figure Presented).
Keywords

Full text: Available Collection: Databases of international organizations Database: EMBASE Type of study: Prognostic study Topics: Variants Language: English Journal: International Journal of Rheumatic Diseases Year: 2023 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: Databases of international organizations Database: EMBASE Type of study: Prognostic study Topics: Variants Language: English Journal: International Journal of Rheumatic Diseases Year: 2023 Document Type: Article